Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw an uptick in trading volume on Thursday . 468,247 shares traded hands during trading, an increase of 43% from the previous session’s volume of 327,331 shares.The stock last traded at $6.75 and had previously closed at $6.32.

Several brokerages recently issued reports on FOMX. Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Guggenheim reissued a “buy” rating and set a $10.00 price objective on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 10th.

The stock’s market cap is $207.55 million. The stock’s 50-day moving average is $6.55 and its 200 day moving average is $6.59.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. On average, analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.89) EPS for the current fiscal year.

A hedge fund recently raised its stake in Foamix Pharmaceuticals stock. J. Goldman & Co LP raised its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned about 1.90% of Foamix Pharmaceuticals worth $4,704,000 as of its most recent filing with the SEC.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.